Anti-Mouse Fas Ligand (MFL3) In Vivo Antibody - Low Endotoxin (ICH1178-25mg)

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

This product is clone MFL3, an Armenian hamster IgG monoclonal antibody raised against mouse Fas Ligand (FasL/CD178, UniProt P41047). The Armenian hamster host and format make it well suited to mouse in-vivo and functional studies, since it avoids the isotype and species pitfalls that complicate rat or mouse anti-mouse reagents in immunocompetent animals. MFL3 recognises the mouse antigen and is validated for blocking, flow cytometry, and immunofluorescence, so it can be used both to interrogate FasL expression on cells and to functionally neutralise FasL-mediated signalling in vitro and in vivo. It is supplied low endotoxin (research grade less than 1 EU/mg; ultra-low option less than 0.5 EU/mg), in-vivo-ready, and available in bulk milligram-to-gram quantities to support repeat dosing across cohorts. All material is for research use only. As with any functional reagent, expression levels, model background, and dosing schedule should be confirmed empirically before drawing mechanistic conclusions. Fas Ligand (FasL, also called CD178, CD95L or TNFSF6) is a type II transmembrane protein of the TNF superfamily and the physiological ligand for Fas (CD95/APO-1). Engagement of Fas by trimeric FasL recruits FADD and caspase-8 to assemble the death-inducing signalling complex, triggering the extrinsic apoptotic pathway. FasL is expressed by activated T cells and NK cells, where it mediates cytotoxic killing and activation-induced cell death that helps terminate immune responses, and it contributes to immune privilege at sites such as the eye and testis. FasL exists as membrane-bound and metalloprotease-cleaved soluble forms, which can differ in their apoptotic versus non-apoptotic signalling activity. Dysregulated Fas/FasL signalling is implicated in autoimmunity, lymphoproliferation, tissue injury, and tumour immune evasion, making FasL a target of interest across immunology and oncology.

FasL is expressed on activated T cells, NK cells, the eye, and testis